Diligence memo · auto-generated · as of July 2, 2026
BluePrint Bio, Inc.
BluePrint Bio, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
BluePrint Bio, Inc. operates in Biotechnology, based in ALISO VIEJO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BluePrint Bio, Inc. has raised $1.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $790K on 2017-01-30.
Most recent recorded round closed around 2017-01-30.
Valuation (modeled)modeled
Provath models BluePrint Bio, Inc. at approximately $44M (range $421K–$495M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.06× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 9.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).
Modeled value ranks above 42% of those peers.
Closest niche peers: New Vital Signs, Inc., Cerebral Magnetics INC, NutriBand Inc., Jivana Biotechnology Inc, AnTolRx, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.